PT. RICHMOND, Calif., Dec. 7 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President & Chief Executive Officer, will participate in an expert panel on “Drug Development in a Changed Environment” at the RBC Capital Markets 2007 Healthcare Conference at the Westin New York Hotel at Times Square on Thursday, December 13, 2007 at 10:00 AM Eastern Time.
The multi-company panel will be moderated by Ken Trbovich, Vice President, Capital Markets at RBC, and will be available at the following link via webcast: http://www.wsw.com/webcast/rbc84/panel24.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the company’s website at: http://www.transcept.com.
mgill@transcept.com scarrington@theruthgroup.comjrando@theruthgroup.com
CONTACT: Michael Gill, Director of Communications of Transcept
Pharmaceuticals, Inc., +1-510-215-3575, mgill@transcept.com; or Investors,
Stephanie Carrington, +1-646-536-7017, scarrington@theruthgroup.com, or
Media, Jason Rando, +1-646-536-7025, jrando@theruthgroup.com, both of The
Ruth Group for Transcept Pharmaceuticals, Inc.
Web site: http://www.transcept.com/
